Share This Author
Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.
Fetal nuchal translucency > or = 3 mm is a useful first trimester marker for fetal chromosomal abnormalities.
Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis.
Hypermethylated RASSF1A is a universal marker for fetal DNA and is readily detectable in maternal plasma when applied to prenatal RhD genotyping, and allows the detection of false-negative results caused by low fetal DNA concentrations in maternal Plasma.
Screening for fetal aneuploidies at 11 to 13 weeks
- K. Nicolaides
- MedicinePrenatal diagnosis
- 1 January 2011
Improvement in the performance of first‐trimester screening can be achieved by firstly, inclusion in the ultrasound examination assessment of the nasal bone and flow in the ductus venosus, hepatic artery and across the tricuspid valve, and secondly, carrying out the biochemical test at 9 to 10 weeks and the ultrasound scan at 12 weeks.
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Treatment with low‐dose aspirin in women at high risk for preterm preeclampsia resulted in a lower incidence of this diagnosis than placebo, and there were no significant between‐group differences in the incidence of neonatal adverse outcomes or other adverse events.
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
- K. Nicolaides
- MedicineAmerican journal of obstetrics and gynecology
- 1 July 2004
Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study
Measurement of fetal nuchal translucency thickness—traditionally used to identify fetuses at high risk of aneuploidy—at 10-14 weeks of gestation can identify a large proportion of fetuses with major defects of the heart and great arteries.
Evolution of Maternofetal Transport of Immunoglobulins During Human Pregnancy
- A. Malek, R. Sager, Peter Kuhn, K. Nicolaides, H. Schneider
- Medicine, BiologyAmerican journal of reproductive immunology
- 1 November 1996
The evolution of the maternal‐fetal transport of immunoglobulins during human pregnancy is determined and the role of breastfeeding in this evolution is determined.
Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers
- R. Akolekar, A. Syngelaki, L. Poon, D. Wright, K. Nicolaides
- MedicineFetal Diagnosis and Therapy
- 16 August 2012
A new model has been developed for effective first-trimester screening for PE based on maternal characteristics, biophysical and biochemical markers based on a survival time model for the time of delivery in which Bayes’ theorem was used.
Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study
Multiplexed maternal plasma DNA sequencing analysis could be used to rule out fetal trisomy 21 among high risk pregnancies and if referrals for amniocentesis or chorionic villus sampling were based on the sequencing test results, about 98% of the invasive diagnostic procedures could be avoided.
Progesterone and the risk of preterm birth among women with a short cervix.
- E. Fonseca, E. Çelik, M. Parra, Mandeep Singh, K. Nicolaides
- MedicineThe New England journal of medicine
- 2 August 2007
In women with a short cervix, treatment with progesterone reduces the rate of spontaneous early preterm delivery and is associated with a nonsignificant reduction in neonatal morbidity.